Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ diflorasone diacetate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Inflammatory Skin Conditions: Diflorasone diacetate is primarily used topically to relieve symptoms associated with inflammatory skin conditions, such as eczema (atopic dermatitis), psoriasis, contact dermatitis, seborrheic dermatitis, and other forms of dermatitis. It works by reducing inflammation, itching, redness, and swelling associated with these skin conditions.

  2. Topical Application: Diflorasone diacetate is available in various topical formulations, including creams, ointments, lotions, and gels, which are applied directly to the affected area of the skin. It is usually applied thinly and evenly to the affected skin once or twice daily, following the instructions provided by a healthcare provider.

  3. Anti-inflammatory Effect: Diflorasone diacetate belongs to the class of medications known as corticosteroids, which exert anti-inflammatory effects by inhibiting the production of inflammatory mediators and suppressing immune responses in the skin. This helps to alleviate the symptoms of inflammation, such as itching, redness, and swelling, and promotes healing of the affected skin.

  4. Vasoconstrictive Effect: In addition to its anti-inflammatory properties, diflorasone diacetate also has vasoconstrictive effects, meaning it causes constriction of blood vessels in the skin. This can help reduce the redness and swelling associated with inflammatory skin conditions and enhance the penetration of the medication into the affected tissues.

  5. Short-term Use: Diflorasone diacetate is typically used for short-term treatment of inflammatory skin conditions to minimize the risk of side effects associated with long-term corticosteroid use, such as skin thinning, telangiectasia (visible blood vessels), and skin atrophy. Treatment duration should be limited to the shortest duration necessary to control symptoms effectively.

  6. Side Effects: Common side effects of diflorasone diacetate may include burning, stinging, itching, dryness, or irritation at the site of application. These side effects are usually mild and transient and may improve with continued use of the medication. However, prolonged or excessive use of diflorasone diacetate may increase the risk of side effects such as skin thinning, stretch marks, or secondary infections.

  7. Contraindications: Diflorasone diacetate is contraindicated in individuals with a known hypersensitivity or allergy to the medication or any of its components. It should not be used on open wounds, infected areas, or areas of the skin affected by certain viral infections, such as herpes simplex or chickenpox.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of diflorasone diacetate,(prescription) On Probiotics

Rank Probiotic Impact
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by diflorasone diacetate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Collinsella genus Decreases 👪 Source Study proinflammatory
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Odoribacter genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Segatella genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Eggerthella genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Bacteroides caccae species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Roseburia intestinalis species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Bifidobacterium longum species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Bacteroides xylanisolvens species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of diflorasone diacetate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.2 0.2
Acne 0.1 -0.1
ADHD 1.4 0 0
Age-Related Macular Degeneration and Glaucoma 0.1 0.3 -2
Allergic Rhinitis (Hay Fever) 0.6 0.4 0.5
Allergies 1.4 0.4 2.5
Allergy to milk products 0.4 0.5 -0.25
Alopecia (Hair Loss) 0.8 0.8
Alzheimer's disease 0.9 1.6 -0.78
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.2 2
Ankylosing spondylitis 1.5 0.1 14
Anorexia Nervosa 0.3 0.4 -0.33
Antiphospholipid syndrome (APS) 0.7 0.2 2.5
Asthma 0.2 0.2 0
Atherosclerosis 0.3 0.8 -1.67
Atrial fibrillation 0.8 0.9 -0.13
Autism 2.5 2 0.25
Barrett esophagus cancer 0.1 0.1 0
benign prostatic hyperplasia 0.1 0.1
Bipolar Disorder 0.7 0.2 2.5
Brain Trauma 0.3 0.2 0.5
Carcinoma 1.5 1 0.5
Celiac Disease 0.9 1.2 -0.33
Cerebral Palsy 0.3 0.4 -0.33
Chronic Fatigue Syndrome 1.3 2.4 -0.85
Chronic Kidney Disease 0.8 0.3 1.67
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.5 0.1 4
Chronic Urticaria (Hives) 0.6 0.2 2
Coagulation / Micro clot triggering bacteria 0.8 0.4 1
Colorectal Cancer 1.4 0.3 3.67
Constipation 0.4 0.3 0.33
Coronary artery disease 0.2 0.2 0
COVID-19 3.9 3.5 0.11
Crohn's Disease 2.3 1.4 0.64
cystic fibrosis 0.4 0.3 0.33
deep vein thrombosis 0.4 0.3 0.33
Depression 4.2 2.5 0.68
Dermatomyositis 0.1 0.1 0
Eczema 0.2 0.4 -1
Endometriosis 1.1 0.2 4.5
Eosinophilic Esophagitis 0 0.1 0
Epilepsy 1 1.4 -0.4
Fibromyalgia 1.5 0.6 1.5
Functional constipation / chronic idiopathic constipation 1.7 1.6 0.06
gallstone disease (gsd) 0.7 0.2 2.5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.4 0.4 0
Generalized anxiety disorder 0.5 0.3 0.67
giant cell arteritis 0.1 -0.1
Glioblastoma 0.1 -0.1
Graves' disease 0.7 0.5 0.4
Halitosis 0.2 0.1 1
Hashimoto's thyroiditis 0.7 0.4 0.75
Hidradenitis Suppurativa 0.3 0.1 2
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.9 0.2 3.5
hypercholesterolemia (High Cholesterol) 0.2 0.2
hyperglycemia 0.1 0.6 -5
Hyperlipidemia (High Blood Fats) 0.3 0.2 0.5
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 1 1.7 -0.7
Hypothyroidism 0.2 -0.2
Hypoxia 0.4 0.4
IgA nephropathy (IgAN) 0.7 -0.7
Inflammatory Bowel Disease 1.2 1.9 -0.58
Insomnia 0.4 0.2 1
Intelligence 0.3 0.1 2
Intracranial aneurysms 0.6 0.2 2
Irritable Bowel Syndrome 1.7 1.2 0.42
Liver Cirrhosis 1.5 0.8 0.88
Long COVID 2.9 2.5 0.16
Low bone mineral density 0.1 -0.1
Lung Cancer 0.8 0.1 7
ME/CFS with IBS 0.5 0.5 0
ME/CFS without IBS 0.3 0.7 -1.33
Menopause 0.4 0.4
Metabolic Syndrome 3.2 2.6 0.23
Mood Disorders 4.8 2.6 0.85
multiple chemical sensitivity [MCS] 0.2 0.1 1
Multiple Sclerosis 1.2 1.6 -0.33
Multiple system atrophy (MSA) 0.6 0.2 2
Neuropathy (all types) 0.3 0.1 2
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.7 1.1 -0.57
NonCeliac Gluten Sensitivity 0.1 -0.1
Obesity 3.5 1.1 2.18
obsessive-compulsive disorder 2.2 0.8 1.75
Osteoarthritis 0.6 0.6
Osteoporosis 0.4 0.3 0.33
pancreatic cancer 0.3 0.3
Parkinson's Disease 1.1 1 0.1
Polycystic ovary syndrome 0.9 0.4 1.25
Postural orthostatic tachycardia syndrome 0.1 0.1 0
Premenstrual dysphoric disorder 0.4 0.3 0.33
primary biliary cholangitis 0.4 -0.4
Psoriasis 1.3 1.1 0.18
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.9 1 0.9
Rosacea 0.3 0.2 0.5
Schizophrenia 1.9 0.4 3.75
scoliosis 0.2 -0.2
Sjögren syndrome 1.1 1.1 0
Sleep Apnea 0.2 0.4 -1
Small Intestinal Bacterial Overgrowth (SIBO) 0.4 0.1 3
Stress / posttraumatic stress disorder 1 0.5 1
Systemic Lupus Erythematosus 1.5 0.5 2
Tic Disorder 0.3 0.3 0
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 1.1 0.7 0.57
Type 2 Diabetes 3.3 1.9 0.74
Ulcerative colitis 0.9 1.6 -0.78
Unhealthy Ageing 1.7 0.4 3.25

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]